Trials for idasanutlin, which targets the MDM2–p53 interaction, and apabetalone, which targets bromodomains, are underway for cancer treatments.16 Venetoclax, which is prescribed to treat chronic lymphocytic leukaemia (CLL), is a BH3-mimetic, resulting in apoptosis of CLL cells due to inhibition of BCL-2 activity.17 Furthermore, stapled peptides targeting MCL-1 protein, a member of the BCL-2 family, are being developed as apoptosis inducers in cancer cells18 and ALRN-6924, a stapled peptide which targets both MDM2 and MDMX, entered clinical trials in 2017 with promising initial results.19 This evidence concerns the gene MDM2 and cancer.